Abstract:BACKGROUND: Epstein-Barr virus (EBV) frequently is measured at high levels in COPD using sputum quantitative polymerase chain reaction (qPCR), whereas airway immunohistochemistry analysis has shown EBV detection to be common in severe disease.RESEARCH QUESTION: Is valaciclovir safe and effective for EBV suppression in COPD?STUDY DESIGN AND METHODS: The Epstein-Barr Virus Suppression in COPD trial was a randomized, double-blind, placebo-controlled trial conducted at the Mater Hospital Belfast, Northern Ireland. Eligible patients had stable moderate-to-severe COPD and sputum EBV (measured using qPCR) and were assigned randomly (1:1) to valaciclovir (1 g tid) or matching placebo for 8 weeks. The primary efficacy outcome was sputum EBV suppression (defined as ≥ 90% sputum viral load reduction) at week 8. The primary safety outcome was the incidence of serious adverse reactions. Secondary outcome measures were FEV1 and drug tolerability. Exploratory outcomes included changes in quality of life, sputum cell counts, and cytokine counts.RESULTS: From November 2, 2018, through March 12, 2020, 84 patients were assigned randomly (n = 43 to valaciclovir). Eighty-one patients completed trial follow-up and were included in the intention-to-treat analysis of the primary outcome. A greater number of participants in the valaciclovir group achieved EBV suppression (n = 36 [87.8%] vs n = 17 [42.5%]; P < .001). Valaciclovir was associated with a significant reduction in sputum EBV titer compared with placebo (-90,404 copies/mL [IQR, -298,000 to -15,200 copies/mL] vs -3,940 copies/mL [IQR, -114,400 to 50,150 copies/mL]; P = .002). A statistically nonsignificant 24-mL numerical FEV1 increase was shown in the valaciclovir group (difference, -44 mL [95% CI, -150 to 62 mL]; P = .41). However, a reduction in sputum white cell count was noted in the valaciclovir group compared with the placebo group (difference, 2.89 [95% CI, 1.5 × 106-7.4 × 106]; P = .003).INTERPRETATION: Valaciclovir is safe and effective for EBV suppression in COPD and may attenuate the sputum inflammatory cell infiltrate. The findings from the current study provide support for a larger trial to evaluate long-term clinical outcomes.TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT03699904; URL: www.CLINICALTRIALS: gov.

Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial

Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial

Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection

Valacyclovir or Valganciclovir for Cytomegalovirus Prophylaxis: A Randomized Controlled Trial in Adult and Pediatric Kidney Transplant Recipients

Lenalidomide Potentially Reduced the Level of Cell- Associated HIV RNA and Improved Persistent Inflammation in Patients with HIV-associated Cryptococcal Meningitis a Pilot Study

Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD

A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation

Anti-Inflammatory Immunomodulatory Activity of Valacyclovir on the in Vitro Activated Mammalian Macrophages

Successful Virologic Outcomes over Time among HAART-treated HIV-infected Patients.

A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.

Use of High-Dose Oral Valacyclovir During an Intravenous Acyclovir Shortage: A Retrospective Analysis of Tolerability and Drug Shortage Management

Acyclovir, cidofovir, and amenamevir have additive antiviral effects on herpes simplex virus TYPE 1

Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients

A potential anti-HIV-1 compound, Q308, inhibits HSV-2 infection and replication in vitro and in vivo

Clinical research of short-term and low dose valaciclovir for cytomegalovirus pneumonia prophylaxis in renal transplant recipients

Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.

Antiretroviral Therapy, Interferon Sensitivity, and Virologic Setpoint in Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Patients

Impact of influenza and pneumococcal vaccines on HIV persistence and immune dynamics during suppressive antiretroviral therapy

In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs

Antiviral potential of phenolic compounds against HSV-1: In-vitro study

Valspodar limits human cytomegalovirus infection and dissemination